Industry News
UQ team to test therapeutic HPV vaccine
A research team at the University of Queensland, headed by Prof Ian Frazer, is said to have developed a new, therapeutic vaccine for genital warts, and is about to begin phase II trials in Australia and China. [ + ]
Liver diagnostic technology
Resonance Health's non-invasive liver diagnostic technology uses magnetic resonance imaging (MRI) technology to provide a scan of the liver which is subsequently analysed to quantify iron loading using FerriScan's proprietary software. It is a novel technology easily applied to anyone with an MRI machine.
[ + ]Eqitx CEO says 'no cash flow issues'
Melbourne-based Eqitx (ASX:EQX) was asked by the ASX last week to explain its financial position following the announcement it had invested a further $500,000 to increase its equity in vaccine developer VacTX. [ + ]
Prana completes Alzheimer's phase I
Melbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease. [ + ]
Over the counter, into the black
Singapore-based, ASX-listed Rockeby Biomed (ASX:RBY) has changed its focus and managing director Dr Sze Wee Tan has a positive outlook for this year. Helen Schuller reports. [ + ]
Why Chance takes no chances on GM
Western Australia's agriculture minister, Kim Chance, is taking what many are now seeing as an overly cautious stance on biotechnology. Graeme O'Neill reports. [ + ]
Industry groups warn PBS changes dangerous for biotech
Widely-touted changes to Australia's Pharmaceutical Benefits Scheme (PBS) could cost the biotech industry more than AUD$300 million in investment annually, according to AusBiotech. [ + ]
Local councils to join Victorian biotech industry
A new study identifying ways that local government can assist the biotech industry was launched by Victorian minister for innovation John Brumby yesterday. [ + ]
Tracking performance in real time
Traqua, developed by the CRC for microTechnology for the Australian Institute of Sport (AIS), is the leading edge of the next sports revolution - providing hard data in real time on an athlete's motion to reinforce the coach's eye and instincts.
[ + ]How viruses enter cells
A team of Northwestern University researchers has solved the structure of a molecule that controls the ability of viruses of the paramyxovirus family, including the viruses that cause measles, mumps, and many human respiratory diseases, to fuse with and infect human cells.
[ + ]In brief: Genesis Biomedical, Select Vaccines, Pharmaxis
Sydney-based Genesis Biomedical (ASX:GBL) has closed its underwritten share offer early and oversubscribed raising AUD$2.4 million, substantially boosting its coffers -- the firm had $586,000 at the end of the quarter. [ + ]
Mesoblast implants two with adult stem cells
The first two patients in Melbourne-based Mesoblast's (ASX:MSB) clinical trials have been implanted with adult stem cells. [ + ]
Ambri boss adds perspective to US partner's decision
Sydney biosensor specialist Ambri (ASX:ABI) appeared to hit a setback last week, when the company announced that its US partner would no longer work to develop Ambri's ion-channel switch (ICS). [ + ]
Psiron chair spells out business plans
Psiron (ASX:PSX) has moved to reassure shareholders of its ability to fund its business plans, in the wake of last week's resignations of the company's CEO and CFO. [ + ]
Glaxo opens Australian Relenza plant
Federal health minister Tony Abbott was on hand to cut the ribbon for the first of two Relenza production lines at GlaxoSmithKline's manufacturing facilities in Boronia, Victoria, last week. [ + ]
